| Name | Finerenone |
| Description | Finerenone (BAY-948862) is a nonsteroidal antagonist of the mineralocorticoid receptor (MR) (IC50=18 nM) with selective and oral activity. Finerenone is used in the treatment of patients with chronic kidney disease with type 2 diabetes. |
| In vitro | METHODS: Human smooth muscle cells SMC and human endothelial cells EC were treated with aldosterone (1-50 nM) and Finerenone (1-10 nM) for 24 h. Cell proliferation was detected by BrdU incorporation assay.
RESULTS: After stimulation with aldosterone, the proliferation rate of SMC increased significantly. Although treatment with 1 nM concentration of Finerenone showed a clear tendency to decrease the SMC proliferation rate, 10 nM Finerenone adequately and significantly blocked aldosterone-induced SMC proliferation. However, aldosterone did not affect EC proliferation in vitro, nor did Finerenone. [1]
METHODS: HK-GFP-hMR cells were treated with aldosterone (10 nM) and Finerenone (1 µM) for 3 h. The gene expression levels were measured by RT-qPCR.
RESULTS: Finerenone was effective in antagonizing some aldosterone-induced genes. [2] |
| In vivo | METHODS: To investigate the effects on vascular remodeling after acute vascular injury, Finerenone (1-10 mg/kg) was administered orally once daily for 21 days to wire-induced femoral artery dilated C57BL/6 mice.
RESULTS: Finerenone treatment inhibited intimal and intermediate cell proliferation after wire-induced injury in mouse femoral arteries at 10 days post-injury and attenuated the formation of neoplastic intimal injury at 21 days post-injury. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (158.55 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6 mg/mL (15.86 mM), Solution.
H2O : Insoluble
|
| Keywords | type | systolic | pressure | oral | nonsteroidal | Mineralocorticoid Receptor | kidney | Inhibitor | inhibit | GlucocorticoidReceptor | Glucocorticoid Receptor | Finerenone | disease | diabetes | chronic | cardiorenal | blood |
| Inhibitors Related | Nimodipine | Betamethasone | Mifepristone | Prednisolone acetate | Beclometasone | Cortisone | Dexamethasone acetate | Dexamethasone | Betamethasone dipropionate | Dexamethasone Phosphate disodium | Prednisone acetate | Megestrol acetate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Drug Library |
United States
